基石药业-B 港股通 空最新增减持 (2026-06-05) 官网 ( 02616.hk) | -15.47 | 10.96 | 0% | 上市时间2019-02-26股价4.70港币涨跌幅-6.19%成交金额6,703.89万港币换手率0.88%市值75.21亿港币H股市值75.21亿港币总股本16.00亿H股本16.00亿每手股数500上市至今年化投资收益率-12.88%港股通持仓占H股比例5.12% (4.04亿港币2026-06-03) 累计做空占H股比例4.02% (5.18亿港币2026-05-29) | |||
| 所属三级行业生物技术 (恒生) | 市盈率 | 97.58 | 市净率 | 3.79 | 股息率 | 0.44% | 恒生:医疗保健业药品及生物科技生物技术 |
| 备注 (2): | 双击编辑备注 |
基石药业-B(02616) - 历史董事名单
| # | 姓名 | 职衔 | 职位 | 委任日期 | 辞任日期 |
|---|---|---|---|---|---|
| 1 | 楊建新 | Executive Director | CEO | 2022-08-25 | -- |
| 2 | HITCHNER III Walton Kenneth | Non Executive Director | 2021-12-10 | -- | |
| 3 | 胡正國 | Non Executive Director | 2021-07-09 | -- | |
| 4 | 林向紅 | Non Executive Director | 2020-11-30 | -- | |
| 5 | 曹彥凌 | Non Executive Director | 2019-05-15 | 2023-01-18 | |
| 6 | CHEW Herbert Paul | Independent Non Executive Director | 2019-02-14 | -- | |
| 7 | 孫洪斌 | Independent Non Executive Director | 2019-02-14 | -- | |
| 8 | 胡定旭 | Independent Non Executive Director | 2019-02-14 | -- | |
| 9 | 陳連勇 | Non Executive Director | 2018-08-14 | 2021-07-09 | |
| 10 | 張國斌 | Non Executive Director | 2018-05-08 | 2020-11-30 | |
| 11 | 童小幪 | Non Executive Director | 2018-02-28 | 2019-05-15 | |
| 12 | JIANG Ning Jun Frank | Executive Director | 2016-11-03 | 2022-08-25 | |
| 13 | 趙群 | Non Executive Director | 2016-04-01 | 2021-12-10 | |
| 14 | 李偉 | Non Executive Director | Chairman | 2015-12-02 | -- |